CYP17A1

(redirected from CYP17)

CYP17A1

A gene on chromosome 10q24.3 that encodes a member of the cytochrome P450 superfamily of enzymes, which catalyse reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP17A1 localises to the endoplasmic reticulum and has 17 alpha-hydroxylase and 17, 20-lyase activities; it is a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens and oestrogens.

Molecular pathology
CYP17A1 mutations are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17, 20-lyase deficiency, pseudohermaphroditism and adrenal hyperplasia.
References in periodicals archive ?
Both cytochrome CYP17 (P-450 17[alpha]-hydroxylase) and cytochrome CYP19 (P-450 aromatase) are involved in estrogen biosynthesis.
Abirateron asetat (AA) bir CYP17 inhibitorudur (17a-hidrolaz ve 17, 20-liyaz inhibisyonunun bir kombinasyonu).
Effects of individual polychlorinated naphthalene (PCN) components of Halowax 1051 and 2 defined, artificial PCN mixtures on AHR and CYP1A1 protein expression, steroid secretion and expression of enzymes involved in steroidogenesis (CYP17, 17-HSD and CYP19) in porcine ovarian follicles.
In 2017, Laekna struck its first deal with Novartis, acquiring global rights to develop a CYP17 inhibitor (CFG920), an oral androgen inhibitor, to treat prostate cancer.
Yonsa is a CYP17 inhibitor which uses proprietary SoluMatrix Fine Particle Technology to create a micronized (smaller particle size) formulation of abiraterone acetate tablets for the treatment of mCRPC in combination with methylprednisolone.
The conversion of pregnenolone to testosterone is achieved by a chain reaction of several enzymes, including 3[beta]-hydroxysteroid dehydrogenase (HSD3B1), 17[alpha]-hydroxylase (CYP17), and 17[beta]- hydroxysteroid dehydrogenase (HSD17B) [1].
In the ?4-pathway in the ZF, cytochrome P-450 17 alpha-hydroxylase (CYP17) catalyzes the conversion of pregnenolone and progesterone to 17a-hydroxypregnenolone and 17a-hydroxyprogesterone, respectively, so the levels of pregnenolone and 17a-hydroxyprogesterone do not vary significantly.
(1) One of these agents is abiraterone acetate (abiraterone), an orally available inhibitor of CYP17 that blocks adrenal and intra-tumoural androgen synthesis.
Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women.
we determine that Petitioner has shown by a preponderance of the evidence that all claims of the '438 patent for which trial was instituted, namely, claims 1-20, are unpatentable." The '438 patent describes administration of a therapeutically effective amount of a CYP17 inhibitor, such as abiraterone acetate, with a therapeutically effective amount of at least one additional therapeutic agent including, but not limited to, an anti-cancer agent, such as mitoxantrone, paclitaxel, docetaxel, leuprolide, goserelin, triptorelin, seocalcitol, bicalutamide, or flutamide, or a steroid, such as hydrocortisone, prednisone, or dexamethasone, the ruling states.
Bezerra de Castro et al., "Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17[beta]1, COMT and MnSOD): possible protective role of MnSOD gene polymorphism Val/Ala and Ala/Ala in women that never breast fed," Oncology Reports, vol.